Oxurion NV Announces Initiation of Equity Analyst Coverage by H.C. Wainwright with a “Buy” Recommendation
04 Novembre 2021 - 07:00AM
Leuven,
BE, Boston,
MA, US –
November 4,
2021 –
07.00
AM CET – Oxurion NV (Euronext
Brussels: OXUR), a biopharmaceutical company developing next
generation standard of care ophthalmic therapies, with a clinical
stage portfolio in vascular retinal disorders, announces that H.C.
Wainwright has initiated analyst coverage.
H.C. Wainwright initiated coverage of Oxurion NV
with a “Buy” rating and a price target of €5. H.C. Wainwright joins
Roth Capital as the second US bank covering Oxurion.
The H.C. Wainwright coverage initiation follows
Oxurion achieving two important recent corporate milestones:
-
Announcing topline positive data from Part A of the Company’s Phase
2 study of THR-149, a plasma kallikrein inhibitor, for the
treatment of patients with Diabetic Macular Edema (DME) who respond
suboptimally to anti-VEGF therapy
-
The start of the Phase 2 clinical study evaluating THR-687, a pan
RGD integrin antagonist, in patients with DME.
All reports on Oxurion prepared by analysts
represent the views of those analysts and are not necessarily those
of Oxurion. Oxurion is not responsible for the content, accuracy,
or timelines provided by analysts.
A copy of the full analysts’ note can be
obtained directly from the banks.
By referring to these analysts or distributing
their opinions, Oxurion does not in any way commit itself to the
validity of such information, conclusions or recommendations.
END
For further information please
contact:
Oxurion NVTom GraneyChief Executive OfficerTel: +32 16 75 13
10tom.graney@oxurion.com Michael DillenChief Corporate
DevelopmentTel: +32 479 783583Michael.dillen@oxurion.com
|
EU MEDiSTRAVA ConsultingDavid Dible/ Sylvie Berrebi/Frazer HallTel:
+44 20 7638 9571oxurion@medistrava.com USWestwicke, an ICR
CompanyChristopher BrinzeyTel: +1 617 835
9304chris.brinzey@westwicke.com |
About Oxurion
Oxurion (Euronext Brussels: OXUR) is a
biopharmaceutical company developing next generation standard of
care ophthalmic therapies, which are designed to better preserve
vision in patients with retinal vascular disorders including
diabetic macular edema (DME), the leading cause of vision loss in
diabetic patients worldwide as well as other conditions, including
wet age-related macular degeneration (AMD) and retinal vein
occlusion (RVO).
Oxurion is aiming to build a leading global
franchise in the treatment of retinal vascular disorders based on
the successful development of its two novel therapeutics:
-
THR-687 is a highly selective pan-RGD integrin antagonist that is
initially being developed as a potential first line therapy for DME
patients. Positive topline results in a Phase 1 clinical study
assessing THR-687 as a treatment for DME were announced in 2020.
Oxurion is currently conducting a Phase 2 clinical trial
(“INTEGRAL”) evaluating THR-687 in patients with DME. THR-687 also
has the potential to deliver improved treatment outcomes for
patients with wet AMD and RVO.
-
THR-149 is a potent plasma kallikrein inhibitor being developed as
a potential new standard of care for the 40-50% of DME patients
showing suboptimal response to anti-VEGF therapy. THR-149 has shown
positive topline Phase 1 results for the treatment of DME. The
company is currently conducting a Phase 2 clinical trial
(“KALAHARI”) evaluating multiple injections of THR-149 in DME
patients previously showing a suboptimal response to anti-VEGF
therapy. Following positive data from Part A of this Phase 2 study
(dose selection), the Company has initiated Part B of the
study.
Oxurion is headquartered in Leuven, Belgium, and
is listed on the Euronext Brussels exchange under the symbol OXUR.
More information is available at www.oxurion.com.
Important information about forward-looking
statements
Certain statements in this press release may be
considered “forward-looking”. Such forward-looking statements are
based on current expectations, and, accordingly, entail and are
influenced by various risks and uncertainties. The Company
therefore cannot provide any assurance that such forward-looking
statements will materialize and does not assume an obligation to
update or revise any forward-looking statement, whether as a result
of new information, future events, or any other reason. Additional
information concerning risks and uncertainties affecting the
business and other factors that could cause actual results to
differ materially from any forward-looking statement is contained
in the Company’s Annual Report. This press release does not
constitute an offer or invitation for the sale or purchase of
securities or assets of Oxurion in any jurisdiction. No
securities of Oxurion may be offered or sold within the United
States without registration under the U.S. Securities Act of 1933,
as amended, or in compliance with an exemption therefrom, and in
accordance with any applicable U.S. state securities laws.
Oxurion NV (EU:OXUR)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Oxurion NV (EU:OXUR)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024